ConductScience.org, home

Paper7688656

Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.

Bruchovsky N and 3 others. Cancer, 1993. Cited by 38 papers, by iCite.

Cite this record

ConductScience Library. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Papers, record 7688656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7688656

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
PubMed
Journal
Cancer
PubMed
Year
1993
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
38
iCite
Relative citation ratio, by iCite
1.34
iCite
Revised in PubMed
2019-06-20
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bruchovsky NN
2Goldenberg SLS L
3Akakura KK
4Rennie PSP S

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cyproterone AcetateMajor topic
DiethylstilbestrolMajor topic
GoserelinMajor topic
Prostatic NeoplasmsMajor topic
Acid Phosphatase
Adult
Aged
Aged, 80 and over
Follicle Stimulating Hormone
Gonadotropin-Releasing Hormone
Humans
Luteinizing Hormone
Male
Middle Aged
Neoplasm Staging
Pilot Projects
Pituitary Gland
Prostate
Prostate-Specific Antigen
Remission Induction
Survival Rate
Testosterone

Source PubMed

Download CSV of topics

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMIDTitleJournalYearIn PapersSource
29624800Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study.Cancer Sci2018https://conductscience.org/library/papers/29624800PubMed
16986003Flare Associated with LHRH-Agonist Therapy.Rev Urol2001https://conductscience.org/library/papers/16986003PubMed
16985931Challenges with luteinizing hormone-releasing hormone agonists: flare and surge.Rev Urol2004https://conductscience.org/library/papers/16985931PubMed
16896883What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?J Cancer Res Clin Oncol2006https://conductscience.org/library/papers/16896883PubMed
15161573Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.Curr Urol Rep2004https://conductscience.org/library/papers/15161573PubMed
14727892Evaluation of Orntide microspheres in a rat animal model and correlation to in vitro release profiles.AAPS PharmSciTech2000https://conductscience.org/library/papers/14727892PubMed
12941195Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer.Curr Treat Options Oncol2003https://conductscience.org/library/papers/12941195PubMed
11057778'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate.Int Urol Nephrol2000https://conductscience.org/library/papers/11057778PubMed
10871814Prostate cancer: a comprehensive review.Med Oncol2000https://conductscience.org/library/papers/10871814PubMed
10870989Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats.Pharm Res2000https://conductscience.org/library/papers/10870989PubMed
10408706Controversies in the management of advanced prostate cancer.Br J Cancer1999https://conductscience.org/library/papers/10408706PubMed
9951446Prostate cancer: 9. Treatment of advanced disease.CMAJ1999https://conductscience.org/library/papers/9951446PubMed
9241550Cyproterone acetate monotherapy in advanced prostatic carcinoma.Int Urol Nephrol1997https://conductscience.org/library/papers/9241550PubMed
7919640Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.Drugs Aging1994https://conductscience.org/library/papers/7919640PubMed
7533693Prospects for pharmacological male contraception.Drugs1994https://conductscience.org/library/papers/7533693PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
KLK3354PubTator's text mininghttps://conductscience.org/library/genes/354

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7688656

GET https://conductscience.org/api/papers/v1/7688656/authors